On June 25, CARsgen Therapeutics fell 5.46% in regular trading, trading at HKD 12.9/share, with turnover of approximately HKD 42.38 million. This marks the third consecutive trading day of decline since the company announced a landmark drug approval.
On June 22, CARsgen announced that its self-developed CAR-T product Satricabtagene Autoleucel received NMPA approval, becoming the world's first CAR-T cell therapy approved for solid tumor treatment. The product is indicated for Claudin18.2-positive, HER2-negative advanced gastric/gastroesophageal junction adenocarcinoma patients who have failed at least two prior lines of therapy. The therapy is priced at RMB 990,000 per dose. Clinical data showed it extends median survival by approximately 5 months compared to best available treatment. The company projects peak annual sales of RMB 2 billion within 4-5 years, with an estimated 200 orders expected this year.
Despite the milestone approval, the stock has fallen sharply — declining 6.36% on June 23 and 6.03% on June 24. The broader biotech sector also weakened, with peers AKESO down 4.57%, Innovent Bio down 2.82%, and Remegen down 3.34%.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments